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ABSTRACT
Current research and development approaches to drug discovery have become less
fruitful and more costly. One alternative paradigm is that of drug repositioning.
Many marketed examples of repositioned drugs have been identified through
serendipitous or rational observations, highlighting the need for more systematic
methodologies to tackle the problem. Systems level approaches have the potential to
enable the development of novel methods to understand the action of therapeutic
compounds, but requires an integrative approach to biological data. Integrated
networks can facilitate systems level analyses by combining multiple sources of
evidence to provide a rich description of drugs, their targets and their interactions.
Classically, such networks can be mined manually where a skilled person is able to
identify portions of the graph (semantic subgraphs) that are indicative of
relationships between drugs and highlight possible repositioning opportunities.
However, this approach is not scalable. Automated approaches are required to
systematically mine integrated networks for these subgraphs and bring them to the
attention of the user. We introduce a formal framework for the definition of
integrated networks and their associated semantic subgraphs for drug interaction
analysis and describe DReSMin, an algorithm for mining semantically-rich networks
for occurrences of a given semantic subgraph. This algorithm allows instances of
complex semantic subgraphs that contain data about putative drug repositioning
opportunities to be identified in a computationally tractable fashion, scaling close to
linearly with network data. We demonstrate the utility of our approach by mining an
integrated drug interaction network built from 11 sources. This work identified and
ranked 9,643,061 putative drug-target interactions, showing a strong correlation
between highly scored associations and those supported by literature. We discuss the
20 top ranked associations in more detail, of which 14 are novel and 6 are supported
by the literature. We also show that our approach better prioritizes known drug-
target interactions, than other state-of-the art approaches for predicting such
interactions.
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INTRODUCTION
Drug repositioning is the process of finding new uses for existing drugs. This process is a
rapidly-evolving issue in the area of drug development, having the potential to reduce
both drug development costs and the time taken for a drug to reach the market. Many
repositioned drugs currently on the market have been discovered through either
serendipitous or rational observations. However, these manual approaches are not
efficient given the potentially huge search space of drug-target (D-T) interactions.
Systematic approaches to searching for repositioning opportunities are required to
provide an efficient and scalable alternative to manual investigations.
A large number of studies have detailed computational approaches to aid in the
systematic identification of drug repositioning opportunities, including methodologies
based on: chemical structure (Keiser et al., 2009), protein structure and molecular docking
(Moriaud et al., 2011), phenotype similarity (such as side-effect similarity (Yang &
Agarwal, 2011) and gene expression similarity (Lamb et al., 2006)) or genetic variation
(Sanseau et al., 2012). Approaches aim to infer links in the drug-target-phenotype-disease
schema (Hurle et al., 2013). For example, side-effect methods link a known drug-
phenotype to a new disease (drug-phenotype-disease). Genetics-based methods,
however, can link targets with a phenotype that is associated with the disease
(drug-target-phenotype-disease) (Hurle et al., 2013). One may also focus on the
prediction of drug-target associations, with the hope that hypothesised links generated
from domain knowledge will allow us to complete a drug-target-disease pathway and infer
a novel use for an existing drug. As well as highlighting potential drug repositioning
opportunities, D-T interaction identification also allows potential adverse side effects to
be analysed (Fakhraei et al., 2014; Dudley et al., 2011).
In vitro approaches to identifying D-T interactions are no different to other aspects of
drug development and remain costly and time consuming (Ding et al., 2014). Using
systematic in silico prediction methods allows for the D-T interaction search space to be
reduced, highlighting areas for focus (Fakhraei et al., 2014). Molecular docking
methodologies are heavily applied to the task, but require a large amounts of computational
resources and are time consuming (Ding et al., 2014). Other approaches involve machine
learning-based methods which may utilise a feature vector approach or, more commonly,
similarity-based approaches which exploit the similarity between drugs and proteins
(Ding et al., 2014). Such approaches allow for the production of prediction models and can
be ligand-based or structure-based. For example, ligand information may be used to create
models that learn which sub-structural features of a ligand correlate with activity against a
particular target (Alvarsson et al., 2014). Other similarity-based approaches make use of a
network, or more specifically a bipartite graph, data representation (Ding et al., 2014;
Fakhraei et al., 2014; Palma et al., 2014; Yamanishi et al., 2008; Yamanishi et al., 2010). Within
a bipartite graph, vertices are divided into two disjoint sets, proteins and drugs. Data from
multiple publicly accessible datasets is integrated during the building of these networks
(Lee et al., 2009), yet in most approaches to D-T interaction prediction data is limited to the
inclusion of the two data ‘types’, protein and drugs.
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More recent approaches to drug repositioning focus on the creation of integrated
networks which combine data from multiple analyses, to give a systems level view
of cellular and molecular processes (Barratt & Frail, 2012; Chen et al., 2012;
Cockell et al., 2010; He et al., 2011; Iskar et al., 2012). This approach provides a
complementary path to reductionist science in understanding complex phenomena.
Semantically-rich integrated networks, which utilise a graph-based representation, are a
convenient method of representing the types of integrated data necessary for finding drug
repositioning opportunities (Betzler et al., 2011). In graph-based data, entities, such as
proteins or drugs, are represented as vertices. Interactions between these entities, such as
protein-protein interactions or a drugs binding to a protein are captured in edges.
In semantic graphs each vertex and edge in the graph is assigned a type from a predefined
set. Vertices and edges are also are annotated with attributes. Graph representations of
complex systems are widely used in computer science, social and technological network
analysis science due to their ability to represent structured and semi-structured data
(Riaz & Ali, 2011). Within bioinformatics graph-based representations are also widely
adopted, particularly as a means of representing data produced during an exercise in data
integration and in protein-protein interactions networks.
In the context of these integrated networks, subgraphs are connected components of
the parent network (Gallagher, 2006). These subgraphs formally capture local
relationships between the elements represented in the graph. Often, the relationships in a
given subgraph are indicative of a particular biological phenomenon. In the case of drug
repositioning networks, the types of relationships include amongst others: interactions
between drugs and their targets, interactions between targets, and the diseases associated
with particular targets. Therefore, within the integrative graph are subgraphs that describe
repositioning opportunities as a result of their semantic and topological properties. Once
appropriate subgraphs have been observed and defined they can be used as templates to
find instances of these subgraphs, and related subgraphs, within a given graph to highlight
similar drug repositioning opportunities.
For example, chlorpromazine is an anti-psychotic drug that is also approved as an
antihistamine (Mitchell, 1993). The interactions of chlorpromazine can be captured in
an integrated network (Fig. 1). Data from DrugBank version 2.5 (DBv2.5) (Wishart,
2006) provides three interactions between chlorpromazine and single protein targets;
none of these interactions explain the antihistaminic affects of the drug. Structurally,
chlorpromazine is very similar to the antiemetic trimeprazine. DBv2.5 captures an
interaction between trimeprazine and the Histamine H1 receptor, a known target for
antihistamines. Through guilt-by-association, we can therefore predict the Histamine
H1 receptor as a target for chlorpromazine, an interaction captured in the latest editions
of the DrugBank database. The topological and semantic properties of the subgraph
depicted in Fig. 1B describe a repositioning relationship that could be generically
applicable to any two drugs and their target. Fig. 1B describes a situation whereby a
compound, structurally similar to a compound with a known target, may also bind to
the same target (the inference is represented as the dashed line). This real example can
therefore be used to derive a template semantic subgraph that can be used for searching
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for similar, but novel, drug-target associations relationships involving different drugs
and targets. This template semantic subgraph therefore describes a pattern indicative of
a drugs interaction with a target, highlighting potential new indications for the drug.
Although Fig. 1 shows a simple triad, semantic subgraphs capturing data relevant to
repositioning opportunities are likely to be more complex. In the context of drug
repositioning, manual identification of potential repositioning opportunities from large
target networks is possible, though not efficient for the systematic analysis of such large
networks. The definition of semantic subgraphs for known repositioning opportunities,
in combination with an algorithm for the mining of integrated complex networks for
these subgraphs, allows us to highlight potential repositioning in a more systematic and
exhaustive fashion.
In this paper we introduce a formal framework for the definition of a semantic
subgraph for integrated networks. We also present DReSMin (Drug Repositioning
Semantic Mining), an algorithm for searching integrated networks for occurrences of a
given semantic subgraph using semantic distance thresholds. DReSMin optimises the
search time for larger subgraphs by including a semantic graph pruning step and applying
a method for splitting large subgraphs prior to searching. We demonstrate the utility of
our approach by searching an integrated drug dataset for semantic subgraphs that are
indicative of drug repositioning opportunities, particularly focusing on inferring D-T
interactions. As part of this work we updated an existing integrated dataset used for
in silico drug discovery (Cockell et al., 2010). Finally we demonstrate that our approach
can be successfully used to predict putative D-T interactions that were not explicitly
represented in the integrated network.
Graphs
Definition of our graph model
A graph G is defined as a ordered pair (V,E), where V is a set of vertices (or nodes), and
E ∈ V  V is a set of edges (or relations). Each e ∈ E is a pair (vi, vj) where vi, vj ∈ V.
sim
binds_to
sim
binds_to
Compound
Target
CompoundTrimeprazine
binds_to
sim
binds_to
Histamine H1 Receptor
Chlorpromazine
sim
A B
Figure 1 An example of a simple semantic subgraph (B) is derived from the repositioning of
Chlorpromazine (A). Chlorpromazine is marketed as a non-sedating tranquilliser, but is also known
to be effective as an antihistamine (Rukhadze et al., 2001) and so in A a relation is inferred between
Chlorpromazine and the Histamine H1 receptor (dashed line).
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Edges represent relations between vertices. Edges may be directed or undirected. Both
vertices and edges may be labelled, typed and attributed.
DReSMin, requires a directed (edges have a direction associated with them) graph
where vertices and edges are labelled with types Tv and Te respectively, where Tv and
Te are drawn from a finite hierarchy of types H, and are annotated with attributes. The
algorithm allows for multigraphs (vertices vi and vj are permitted to have multiple edges
between them) and for vertices to contain self-loops (vi may have an edge directed toward
itself). For the remainder of this paper jV(G)j will be used to represent the number of
vertices contained in graph G.
Classical subgraph definition
Subgraph isomorphism is a task in which two graphs, G & Q are given as input and one
must determine whether G contains a subgraph that is isomorphic to Q: is there a
subgraph G ′(V ′,E ′): V ′4 V,E ′4 E ? During the search of a query graph, a mapping (M)
is expressed as the set of ordered pairs (v,m) (with v ∈ G and m ∈ Q) and soM = {(v,m) ∈
VG  VQjv is mapped onto m}; that is M: G ′1 Q.
Semantic subgraph definition
A semantic subgraph is defined as Q = (V,E,Tv,fv,Te,fe), where V is a set of vertices,
E is a set of edges, Tv is a set of node types and Te is a set of edge types. fv : V9 Tv and
fe : E9 Te are surjective functions; each node is assigned a node type and each edge
an edge type from Tv or Te respectively. A semantic subgraph may be designed in
such a manner that mappings, or occurrences, in G aid in the inference of a relation
between vertices of a particular te, where a relation does not exist. For example, one may
use the semantic subgraph depicted in Fig. 1B to infer an interaction between a compound
and a target.
Graph matching
Several approaches have been described for combining semantic information with
network motif topology including the list coloured motif problem (Betzler et al., 2011;
Lacroix et al., 2006). In this case a motif (M) is defined as a multiset of colours, or types.
An occurrence ofM is a subset of vertices that forms a connected subgraph whose multiset
of colours, or types, matches that of M exactly (Lacroix et al., 2006). Although this
approach demonstrates how network motifs may be extended to incorporate semantic
information, it does not allow for topological exacts to be identified. The ability to
identify sub-components of a target network that match a defined topology is a necessity
in situations where the topology of a subgraph is believed to aid in describing the
functionality of the sub-component. The task of identifying mappings of a predefined
subgraph with similar topology from a larger graph is known as the graph matching
problem (Gallagher, 2006).
There are different variations of the graph-matching problem. For example, exact
matching occurs when the mapping between the vertices of the two graphs is
edge-preserving; a mapping contains all edges defined by the query. One of the most
stringent forms of exact matching is subgraph isomorphism (Conte et al., 2004) which aims
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to find all occurrences of a query graph and is an NP-complete problem (Washio &
Motoda, 2003). Currently, algorithms addressing this problem are exponential in
performance relative to the size of the input graphs (Gallagher, 2006). Many algorithms
which have been developed to address the subgraph isomorphism problem are based on
the exhaustive algorithm developed by Ullmann (1976). Applying an exhaustive method
to the identification of drug repositioning opportunities is important to ensure all
possible novel applications for a drug are investigated. Using a backtracking approach,
Ulmann’s algorithm finds solutions by incrementing partial solutions or abandoning
them when determining they cannot be completed (Ullmann, 1976). An extension of the
Ullman approach, incorporating the semantics of a graph, has been implemented using
inexact (Djoko et al., 1997), as well as exact approaches (Cordella et al., 2004; Giugno &
Shasha, 2002). However, as yet, none of these approaches have been applied to the
automated identification of drug repositioning opportunities.
Whilst searching for semantic subgraphs it is important to consider the similarity
between the query subgraph and the target, both in terms of graph topology and the
meaning of the annotations on vertices and edges. A measurement of semantic similarity
between elements of a mapping and the equivalent element in a query must be introduced
to the search and the degree of similarity can be expressed as a semantic distance.
Numerous measures have been developed to score the semantic similarity between two
ontological concepts (Ge &Qiu, 2008;Noy, 2004). Previous work in the area of intelligence
link analysis has used ontology-based semantic similarity scoring methods for pattern
matching (Seid & Mehrotra, 2007). In Seid and Mehrotra’s algorithm, an inexact
topological search is carried out with matches semantically scored based on their Least
Common Ancestor (LCA) within an ontology. Topological and semantic scores are then
combined and k ranked matches returned.
Whilst approaches described are adequate for their particular setting, here we present a
new exhaustive graph matching approach to aid in the identification of potential drug
repositioning opportunities from a target network. We therefore describe an algorithm for
this task which is an improvement on those introduced for the purpose of drug
repositioning.
MATERIALS AND METHODS
Algorithm
We have developed DReSMin, an algorithm for the detection of semantic subgraphs. This
algorithm returns all mappings of a semantic subgraph that match at a level equal to, or
above a given threshold, ST. In this case our application for the algorithm is the
identification of a semantic subgraph (Q) which may be indicative of drug repositioning
opportunities within a target graph (G). Examples of semantic subgraphs may be initially
drawn from a set of templates, that is the graph representation of known repositioned
drugs, such as chlorpromazine, shown in Fig. 1A. The algorithm is made up of four main
components which are described in Fig. 2. These components comprise: (i) Semantic
graph pruning (ii) Topological search (iii) Semantic subgraph distance exclusion
(iv) Semantic subgraph splitting.
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Semantic graph pruning
We are concerned only with identifying semantic subgraphs that match, semantically, at a
level equal to, or above our threshold. (Note: In this work, the semantic distance between
two graph entities is calculated using the semantic distance calculator described in the
‘Semantic subgraph distance exclusion’ section.) In this graph pruning component of the
algorithm, any vertices (and their associated edges) in G which are above a certain
semantic distance from those in Q are removed from G. This step allows any vertices
that are semantically distant from our query to be removed prior to a search, cutting
down the search space. Taking G, Q and a semantic threshold (ST) each tv ∈ Tv(Q)
are sent to the semantic subgraph distance calculator (termed SDC and described
later in the manuscript), and scored against every tv ∈ Tv(G). If SDC(tv(Q),
tv(G)) < ST then all v ∈ V(G) of type tv are removed from G as well as any e ∈ E
where v = vi or v = vj. Finally after all semantically insignificant elements are removed
from G, all isolated v ∈ V(G) that may have resulted from the edge pruning step
are also removed.
Topological matching
Many algorithms addressing the problem of subgraph isomorphism build on Ullman’s
work. These applications include: GraphQL (He & Singh, 2008), GADDI (Zhang, Li &
Yang, 2009) and, one of the most efficient, the VF algorithm (Cordella et al., 1999).
Performance is increased in these algorithms by exploiting different join orders, pruning
rules and auxiliary information to prune out negative candidate subgraphs as early as
possible. We carry out topological matching using a variation of the VF algorithm
(Cordella et al., 1999). The VF algorithm is exhaustive and suitable for working with ‘large’
graphs (up to 3  104 vertices) and employs a depth-first strategy implemented in a
recursive fashion (Cordella et al., 1999). During a search using the VF algorithm, the
search space is minimised via the introduction of topological pruning rules
(Cordella et al., 1999). Integrated networks typically surpass the aforementioned ‘large’
graphs in size, particularly true within the biological and pharmaceutical settings.
As data volumes continue to grow (e.g. omics technologies continue to mature)
it is important to develop exhaustive algorithms capable of scaling
with the data.
JGraphT Instance of G
Semantic Sub (Q)
Semantic Sub Splitting (Q)Semantic Graph Prune (G)
Topological Matching (G,Q)
Semantic Subgraph Exclusion (ST, Q, M’)
Ranked M
Target Graph (G) Semantic Threshold (ST)
Figure 2 Overview of the DReSMin algorithm developed for the detection of semantic subgraphs
indicative of repositioning opportunities.
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Our initial implementation of the VF algorithm showed poor scalability and so, as an
enhancement to the VF algorithm, we introduce three steps to improve the efficiency of
searching for topological subgraphs. These three steps include: a set of rules used to
determine the appropriate vertices at which an instance of the search is started (initial
candidate set), as described in (1) below; a topological pruning rule, based on a closed
world assumption, as described in (2) below; and a semantic thresholding step (described
in the next section of the manuscript). As the focus of this work is the inference of
associations involving compounds, it is vital that all mappings resulting from a search
contain a node of this particular semantic type.
1. When considering an initial candidate set of nodes from the target graph G at which to
initiate the search, it is desirable to try to ensure that the set is made up of nodes of a
type, X, such as Compound to ensure the relevance of the portion of graph being
searched. Therefore, an initial candidate set for the search is chosen based on:
all v ∈ V(Q) whose tv ∈ Tv(Q) = X are considered with v > degQ(v) (where deg represents
the degree of a node) selected as v. m is made up of all v ∈ V(G) whose degG(v) 
degQ(v) and tv ∈ Tv(G) = X.
2. When mining with a given semantic subgraph that describes a potential
repositioning situation we must assume that the lack of a relationship between nodes
indicates the absence of a relationship between the two nodes (a closed world
assumption). As a result, when searching for a given semantic subgraph, Q, we only
consider a match if there exists no additional edges between the vertices in a mapping
M from the target graph G, and their equivalent vertices in Q. Therefore, a mapping
M is expressed as a set of ordered pairs and the closed world assumption
requires (M = match) ∨ (deg(v) ∈ (G) h deg(m) ∈ V(Q)).
Semantic subgraph distance exclusion
Semantic thresholding is used to exclude matches found in G that are below a given
semantic distance from Q. This process is achieved through a semantic subgraph distance
calculator (SDC). An SDC comprises of two distance matrices, one for tv ∈ Tv(G) and
one for te ∈ Te(G). We have n = 19(tv) and n = 42(te) =_ each matrix is represented as
matrix P ′ = (pij), the n  n matrix defined by;
pij ¼
1 ifpi is semantically identical to pj;
0 ifpi is semantically unrelated to pj ;
1 ifpi is semantically opposite to pj:
8<
: (1)
During the matching process each element of M = (Vm,Em) is scored against its
equivalent in Q = (Vs,Es). The resulting semantic score (SS) of M is;
X SDCðm1; q1Þ; SDCðm2; q2Þ::::SDCðmn; qnÞ
n
(2)
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A semantic threshold (ST) is defined by the user prior to a search; a value ranging from
0 to 1. During the search, vertices and edges pass or fail the semantic threshold. Thus we
identify topological exacts and semantic closeness.
Semantic subgraph splitting
This component takes a semantic subgraph,Q, and returns a set of semantic subgraphs,D,
whose jVj < 4. In Fig. 2, we see how this step interacts with the other components of
DReSMin. ∀d ∈ D produced during this step of DReSMin the target network,
G, is pruned using the semantic graph prune component and d, before d is searched for in
G. The graph splitting component allows smaller subgraphs to be searched and mappings
joined based on sharing a common overlapping node (ON). In order for this approach to
be successful a semantic subgraph is first converted to an undirected graph. The most
connected node, vmax(Q), is then identified and used as ON. Of all the remaining
v ∈ V(Q), the two most distant vertices (v1, v2) from Q are selected. Two new graphs
(D1 & D2) are then created and populated with nodes as such: V(D1) ∪ v ∈ d(v1, ON),
V(D2) ∪ v ∈ d(v2,ON), that is every node in the shortest path from v1 toON is included in
D1 and every node in the shortest path from v2 to ON is included in D2. Remaining
vertices are then allocated depending on which graph they share a connecting edge
with Fig. 3. Edges are then allocated as such: ∀e ∈ E(Q) if either V(D1) or V(D2)
contains both (vi, vj) of e; e is allocated to that graph. Any edges whose nodes are are not
found in the same graph are not allocated to the split subgraphs. As a result of this process
during a search we have D1 and D2 as well as our original semantic subgraph, Q. A search
is then started with D1 or D2, depending on which has the smallest jVj. The search is
started usingON, maintaining the edge set it possessed inQ, reducing the initial candidate
set. All starting vertices that lead to an embedding being identified are then passed to the
v6v5v5 v6
v6v5
v3
v4
v2
D1
D2
v1
v3
v3
D2.1
D2.2
v4v3
Q
v2
v1
v3 v4
Figure 3 Subgraph split procedure takes an initial semantic subgraph (Q) and produces two smaller
semantic subgraphs (D1 and D2) using all vertices (v) from (Q). The overlapping node (ON) is
identified in Q(v3) and used as the overlapping node in both D1 and D2. The two most distant vertices in
Q are then identified (v1 and v6) and vertices in the path between these and ON added to the corre-
sponding graphs (D1 and D2). We also see that jV(D2)j > 3 and so a second call is made to graph split
giving us D21 and D22.
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second search; reducing the initial candidate set once more. All matches from the two
searches who share a common ON are then mapped and a final check for any e ∈ E(Q)
that were not allocated to eitherD1 or D2 is made. This splitting may be called iteratively if
either D1 or D2 still possess a jVj > 3 after the first round of splitting, as demonstrated in
Fig. 3. Subsequent searching will result in the same set of mappings that would be
identified by a non-split search (for algorithm pseudo-code and discussion please
see Article S1).
Ranking inferred interactions
Scoring of a semantic subgraph, Q, is achieved by determining the number of known D-T
interactions in the predicted total set of D-T interactions inferred by Q. We refer to the
complete set of inferred interactions asQ(I). A score Rq is calculated based on the ability of
Q to identify D-T interactions captured in DBv3, but not present in our Dat integrated
data set (see next section). The set of interactions that are captured in DBv3, but not
captured in Dat is known as DBv3Rel (Eq. 5).
RqðQÞ ¼ QðIÞ \ DBv3Relj j
QðIÞj j (3)
Once Rq is calculated for each semantic subgraph we then score individual D-T
interactions, i, based on the cumulative score of all semantic subgraphs that
predicted i.
RiðiÞ ¼
X
i2Q0ðIÞ
RqðQ0Þ (4)
DReSMin is an exhaustive algorithm, as such, scoring inferred interactions allows for
ranking, with those ranked higher inferred with greater confidence than others.
Characterisation and application
An integrated dataset for in silico drug discovery has been described previously by Cockell
and co-workers (Cockell et al., 2010). This dataset satisfies the requirements described for
our algorithm (see ‘Definition of our graph model’ section) and so was used to test the
algorithm performance and mined for D-T interactions using a Java based
implementation of DReSMin.
The dataset was developed in Ondex (Ko¨hler et al., 2006) and includes compounds
and targets from DrugBank1 (Wishart, 2006), Proteins from UniProt2 (UniProt
Consortium, 2013) as well as information from eleven other databases and analysis
methods (Cockell et al., 2010). An updated version of this dataset was used as a test bed for
this work, however the approach we describe is valid for most integrated networks that
adopt a semantically rigorous approach to edge and vertex type definition.
Utilising a graph-based data representation and providing a framework for
visualisation, both vertices and edges within an Ondex graph are annotated with
semantically enriched metadata. Each vertex (or concept) is assigned a c ∈ C, where C is a
finite set of conceptClasses, while each edge or relation is assigned a r ∈ R where R is
a finite set of relationTypes (Ko¨hler et al., 2006). As part of this work we developed
1http://www.drugbank.ca.
2http://www.uniprot.org.
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plug-ins (parsers and mappers) for the Ondex platform to extend the original dataset.
These plug-ins allowed us to add disease conceptClass, taken from the National Drug
File Reference Terminology (NDF-RT)3. Four relationTypes showing interactions
between Disease-Disease (has_parent and has_child) and Compound-Disease
(may_treat and may_prevent) originally defined in NDF-RT were also integrated.
A final relationType between Target-Disease (involved_in) was integrated from
DisGeNET4 (Bauer-Mehren et al., 2010). The updated dataset, which we refer to as
Dat from here on in, has an additional 4,463 vertices (155,316) made up of 19
conceptClasses (see Table S1) in comparison to the original, together with an
additional 28,736 edges (816,096), representing 42 relationTypes (see Table S2). The
metagraph of the dataset described is shown in Fig. S1, with a subsection shown in Fig. 4.
This graph shows a high degree of connectivity with a dS(G) (average node degree) of
10.42, whereby degrees of vertices range from d(G) (minimum degree) of 1 and (G)
(highest degree) of 15,004. Average connectivity differs between conceptClasses, with
Proteins displaying the highest dS(G) of any conceptClass at ∼45. Other notable
connectivity averages include Target ∼13, Compound ∼7 and Disease ∼4. All searches
presented here were carried out using a semantic threshold (ST) of 0.8 (see Article S2). We
only include vertices of type Compound in our initial candidate set.
Drug-Target interaction prediction evaluation
We compared our ranked set of predicted D-T interactions to those produced by another
state-of-the-art method for drug target interaction prediction–a ligand-based method.
One implementation of such an approach is provided by ChEMBL5. ChEMBL provide
two models for target prediction, using bioactivity data with a cut-off of 1 µM and 10 µM
respectively. These models allow for n predicted interactions to be made for a given drug.
Inferred interactions are also scored and can be ranked, meaning a direct comparison to
our approach can be achieved. Predictions using the ChEMBL models can be found in
compound report cards, accessed via their website.
Compound
may_prevent
sim
involved_in
has_parent
Disease
has_similar_sequence
binds_to
may_treat
has_child
is_a
Target
has_similar_sequence
Enzyme
Protein
is_a
interacts_with
Figure 4 A subsection of the Ondex in silico drug discovery dataset metagraph. Shows how different
conceptClasses (E.g. Compound & Target) interact via relationTypes (binds_to).
3VA National Drug File Reference Termi-
nology. <http://www.nlm.nih.gov/
research/umls/sourcereleasedocs/current/
NDFRT>
Accessed September 2013.
4Gene-disease association data were
retrieved from the DisGeNET Database,
GRIB/IMIM/UPF Integrative Biomedical
Informatics Group, Barcelona. <http://
www.disgenet.org/>.
Accessed September 2013.
5https://www.ebi.ac.uk/chembl/.
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Mappings between DrugBank and ChEMBL compounds were retrieved from UniChem
(Chambers et al., 2013) via whole source mapping6. This mapping provides a set of
3,765 drugs that are contained in both datasets, of which 57 of the ChEMBL ids mapped
to >1 DrugBank ID (one to four, five to three, and 51 to two). DReSMin inferred D-T
associations for 2,223 of drugs common to both databases. In the comparison presented
below we only consider D-T interaction inferences involving this set of 2,223 drugs. The
set of inferences from DReSMin contained a total of 2,456 protein targets (of which
1,133 are from Homo sapiens and 1,323 from other organisms). The set of ChEMBL
inferences involve 870 human protein targets, of which 362 are also captured in DReSMin
inferred D-T associations.
For each of the 2,223 drugs, we identified associations with single proteins. The top 100
of these associations were identified using the ChEMBLWeb resource client7. Any
interactions which were already captured in Dat, involved targets from organisms other
than humans or were not captured in the overlapping 362 protein targets, were excluded
from the analysis. This process was repeated for both the 1 µM and the 10 µM ChEMBL
models, giving us two sets of predicted D-Tassociations. In order for a fair comparison to
be made for each of the 2,223 drugs the top x8 inferred single protein targets were
collated and ranked. This process resulted in three sets of 215,075 ranked drug-target
interactions; DReS, Chem1 and Chem10.
Target class comparison
We identify five human protein target classes based on their sizes and importance, as
described by Bull & Doig (2015). Proteins are classified as one of the following: G prote–
incoupled receptors (GPCR); ion channels; kinases; proteases; and other. In order to do this
we use the same approach described by Bull & Doig (2015). Protein family membership is
determined using multiple protein sources. The first is the id attribute of a keyword (k)
element within a UniProt9 entry E. All keywords assigned to E are captured in the set K.
If “KW-0297” in E(K) then E is classed as a GPCR; if “KW-1071”, “KW-0851”,
“KW-0107”, “KW-0869”, “KW-0407”, “KW-0631” or “KW-0894” is in E(K) then E is
classed as an ion channel; if “KW-0418”, “KW-0723” or “KW-0829” is in then E(K) then
E is classed as a kinase; if “KW-0031”, “KW-0064”, “KW-0121”, “KW-0224”, “KW-0482”,
“KW-0645”, “KW-0720”, “KW-0788” or “KW-0888” is in E(K) then E is classed as a
protease; and finally all other proteins are classed as ‘other’. A protein is also classified as a
GPCR, kinase or protease if it appears in the GPCR10, kinase11 or protease12 files
respectively.
RESULTS
Characterisation and performance of DReSMin
We evaluated the effectiveness of each step of our algorithm by adding each step (initial
candidate set selection, topological pruning and semantic distance thresholding)
sequentially to the basic topological search algorithm and then comparing the efficiency of
each modified version to the VF2 topological search. The algorithm was implemented on
a 20 node Ivy-Bridge bioinformatics cluster. Performance was measured as the time taken
6www.ebi.ac.uk/unichem/ Accessed 22nd
June 2015.
7https://github.com/chembl/chembl_
webresource_client.
8x = 100 or, if DReSMin inferred <100
targets for this drug, x = number of
DReSMin inferred targets.
9http://www.uniprot.org Accessed July
30th 2015.
10http://www.uniprot.org/docs/7tmrlist.
txt Accessed Nov 11th 2015.
11http://www.uniprot.org/docs/pkinfam.
txt Accessed Nov 11th 2015.
12http://www.uniprot.org/docs/peptidas.
txt Accessed Nov 11th 2015.
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for a complete search for a semantic subgraph (Q) within a given target graph (G).
Random semantic target graphs (Ran) as well as random semantic subgraphs were
produced in order to evaluate the performance of the semantic subgraph search strategy.
These random graphs were formulated using an approach that attempted to replicate the
semantic and topological properties of Dat. In these random target graphs ∀v ∈ V(Ran) of
type tv, the average deg
−(tv) and the average deg
+(tv) were maintained ∀tv ∈ Tv(Dat).
Experiments were repeated 10 times.
The SDC and graph-pruning step display linear running times ofO(n); with the former
capable of scoring 8  104 concept pairs per second and the latter taking <1 second to
prune a graph G, with jV(G)j of 1  106. During the performance measures we focused
on semantic subgraphs with between 3–6 vertices. The effect on search time when altering
semantic subgraph edgeset size was also examined (Fig. S2) showing an improvement in
performance as the edgeset size increases. This performance increase is due to the fact that
fewer nodes satisfy the more stringent topological rules. With more stringent pruning
during a run of the algorithm the search space at each state is reduced; ultimately meaning
that when searching for semantic subgraphs who share the same jVj but have differing jEj,
the semantic subgraph with the > jEj will be more efficient to search for.
Once semantic subgraphs reach a jV(G)j of 4 then restricting the initial candidate set to
include only Compounds improves performance. It is at this point the benefits of reducing
the initial candidate set successfully reduce the search space, concomitantly increasing
performance (Fig. 5). A similar phenomenon is observed with the introduction of the
closed world check, whereby the real performance benefits are apparent when semantic
subgraphs reach a jV(G)j of 4 (Fig. 5). By restricting the initial candidate set as well as
using the closed world assumption a two fold increase in performance in comparison to a
purely topological approach was observed. Performance is further enhanced when
utilising the semantic distance calculator demonstrating an almost 10 fold performance
boost when comparing to the purely topological approach.
The semantic graph prune step introduces a small but noticeable increase in
performance to DReSMin. Despite an overall increase in performance the graph prune
step also brings a subtle cost; any potential matches containing an element that scores <ST
when passed to the SDC will not be returned. It is for this reason that the graph pruning
step is an optional add-on to the DReSMin algorithm. The graph pruning step is most
useful when one wishes to return matches that are semantically exact to the semantic
subgraph being used as a query (Q). The graph split step can potentially reduce the search
time for Q from that of a jV(Q)j of 6 to one closer to the sum of a search for a subgraph
with a jV(Q)j of 3 and a subgraph with a jV(Q)j of 4. It is this step that produces the
greatest improvement to performance. For example, when using the SDC to search for
Q, where jV(Q)j = 6 in G when jV(G)j = 1  105, takes 60 seconds, using the graph split
method reduces this search time to just over 8 seconds, a 7 fold increase in performance.
Overall, when using all three of the algorithmic steps in DReSMin, the performance
of DReSMin showed performance characteristics approximating a linear scale closer to
O(n). This is in contrast to the exponential scaling characteristics observed for the
purely topological search algorithm, VF2. These DReSMin performance
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characteristics were observed for semantic subgraphs of size jV(Q)j ≤ 6 (Fig. 5). Using
DReSMin with the hardware described above it is possible to complete an exhaustive,
exact search for a 6 node semantic subgraph in a target graph containing >1.5  105
vertices in under 10 seconds. The accuracy of the algorithm does not decrease as
the target graph connectivity, or jEj, increases (Fig. S3) or as the target
graph jVj increases (Fig. S4).
Application to search for drug-target interactions
Semantic subgraphs were identified in Dat and used to infer novel potential D-T
interactions in Dat using the DReSMin algorithm. To aid in this process we utilised more
recent D-T versions of the DrugBank datasets that were not used to build Dat. This
approach allows us to determine if D-T interactions inferred fromDat using DReSMIn are
likely to be supported asmore knowledge is obtained.We can thus understand if inferences
made have any potential value to drug repositioning now, as opposed to in the future.
To carry out this process the D-T interactions from DBv2.5 that were integrated into
Datwere retrieved and captured in the setDatRel. We used DBv2.5 to constructDat in this
exercise even though later releases of DrugBank are available; v3.0 (DBv3) and v4.2
(DBv4.2) (Knox et al., 2011). DBv3 contains additional drugs, targets and their
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Figure 5 Overview of algorithm performance with semantic subgraph (Q) queries nodeset jV(Q)j
ranging from 3–6. Graphs show each step of the algorithm reducing search time. Abbreviations:
VmaxG, initial candidate set is chosen using the vt of the node displaying the highest connectivity in Q;
COMP, compound makes up the initial candidate set; CW, closed world check implemented; SDC,
semantic distance calculator used during search; GP, semantic graph prune step implemented; GS, graph
split used. 5a (all steps plotted for jV(Q)j = 5) and 5b (focuses on GP and GS of jV(Q)j = 5). Algorithm
Performance (bottom right) shows the best approach for each semantic subgraph size.
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interactions to those already contained in Dat (Table 1) and 8,768 additional D-T
interactions to those found in Dat. Of these interactions, 2,919 involve drugs and targets
that are present in Dat, but the interaction relationship had not yet been defined (i.e. the
D-T interaction had not been annotated in DBv2.5). In this work, we refer to these 2,919
interactions from DBv3 as being ‘relevant’. These relevant interactions are represented in
the set DBv3Rel (see Eq. 5) and were used to derive a query set of semantic subgraphs that
were in turn used to mine Dat. DBv4.2 was then used as a reference to validate the new
repositioning opportunities identified through the mining of Dat.
DBv3Rel ¼ DatRel [ UniqueðDBv3Þ j d 2 DatRelðdÞ ^ t 2 DatRelðtÞf g (5)
Semantic subgraphs inferring drug target interactions
Semantic subgraphs can be derived through manual exploration of the graph and by
reference to known repositioning examples. However, in this work, in order to
exhaustively test the DReSMin algorithm, we derived an automated method for
producing a set of semantic subgraphs that would be appropriate for systematically
mining for new D-T interactions. In order to produce such a set, we extracted the portions
of the network in Dat that contained drugs and targets from the 2,919 D-T interactions
whose interaction was annotated later in DBv3Rel. To extract the subnetworks, each drug
and target pair was identified in Dat and the subnetwork represented by the shortest path
between them was extracted as a semantic subgraph (Fig. 6). To identify the shortest
semantic subpaths, Dat was converted to an undirected graph and a Java implementation
of Dijkstra’s shortest path algorithm (Dijkstra, 1959), from the JGraphT13 library used. On
carrying out this semantic subgraph identification exercise 194 different subgraphs with a
jVj < 10 were found to cumulatively identify more than 95% of the D-T interactions
in DBv3Rel and were used as a reference set for D-T inference using DReSMin as
described below.
Inference of novel drug-target interactions
The 194 semantic subgraphs were used as queries to search Dat using DReSMin to test the
ability of the algorithm to identify D-T interactions in Dat that had not yet been
annotated in DBv2.5 (but are present in DBv3). DReSMin was used to identify subgraphs
in Dat that were similar to the query set of semantic subgraphs and therefore with the
potential to be indicative of novel D-T interactions and ultimately aid in the identification
Table 1 Drug, Target and Drug-Target (D-T) Interactions present in the Dataset and DBv3.
Drug Target D-T Interaction Unique Relevant
Dat (DBv2.5) 4,772 3,037 9,227 – –
DBv3 6,180 4,080 14,570 8,768 2,919
DBv4.2 6,377 3,601 14,157 8,673 2,940
Notes:
Unique: refers to interactions not found in Dat, Relevant: subset of Unique interactions, whereby both the drug and
target can be found in Dat.
Of these 333 are unique to DBv4.2 (i.e they are not captured in DBv3).
13http://jgrapht.org.
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of drug repositioning opportunities. After an exhaustive search of Dat with the
194 semantic subgraphs a set of mappings (or instances) of each subgraph was identified.
Semantic subgraphs were scored on their ability to identify D-T interactions captured in
DBv3Rel (using Eq. 3), with these scores ranging from 0.0 to 0.06589 (Table S4). A single
D-T interaction can be inferred by mappings of more than one query semantic subgraph,
thus adding confidence to the prediction that a D-T interaction exists. Therefore, in order
to rank the D-T interactions in terms of confidence, the scores assigned by all query
semantic subgraphs that produced a mapping containing a potential D-T interaction were
summed (using Eq. 4). The Rq of the scores of all 194 query semantic subgraphs was
0.9499 (Fig. S5) and so inferred D-T interaction scores contained within mappings could
potentially, range from 0.0 to 0.9459. The top ten performing subgraphs, and a larger
illustrative subgraph, are shown in Fig. 7.
A search of Dat with the set of 194 semantic subgraphs described above resulted in
906,152,721 mappings. These mappings now captured the potential drug target
interactions in the structure of the mapping subgraph. The 906,152,721 mappings
predicted 9,643,061 D-T interactions that were ranked as described above. Unsurprisingly,
we identify the interactions from DBv3Rel that were used to create the semantic
subgraphs. Importantly, however, these interactions score highly, which indicates that a
single interaction was identified by multiple semantic subgraphs. The D-T interactions
fromDBv3Rel consistently scored better and ranked higher than the unsupported inferred
associations (Figs. 8A and 8B). We also observe that the D-T interactions subsequently
annotated and captured in DBv3Rel are identified by two fold the number of semantic
subgraphs that infer D-T associations not annotated and present in DBv3Rel (Fig. 8C).
BA C
T1 T2 T2T1T1
D2D1 D1D2D1
bi_to
bi_to
h_s_s
h_s_s
sim
sim bi_to
sim
sim
h_s_s
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Figure 6 Semantic subgraphs were derived from the semantic shortest paths between a drug and a
target pair captured in DrugBank v3. (A) shows a drug-target interaction captured in DBv3 made up of
a drug (D1) and a target (T2) captured in our network, Dat. In order to create semantic subgraphs D1
and T2 are identified in Dat (highlighted in green in B) and the semantic shortest paths between the two
nodes calculated (highlighted in red in B). Finally all semantic node types and edge types that fall on the
semantic shortest path are used to create a query graph (C).Note:Dashed red line represents the inferred
binds_to relations, squares represent compounds, circles targets, diamonds proteins and octagon dis-
eases. For relation types: bi_to = binds_to, sim = similar_to, h_s_s = has_similar_sequence.
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However, in order to quantify the predictive power of DReSMin we examined how
many of the high scoring D-T predictions were subsequently annotated in DBv4.2. DBv4.2
contains 333 interactions not captured in DBv3 or Dat. In this work, these interactions are
represented in the set DBv4Rel (see Eq. 6). These 333 new interactions had not been used
to construct the semantic subgraphs used for searching Dat. Of the 333 D-T interactions
captured in DBv4Rel, 309 were successfully identified (94%). We also observed high
ranking and scoring of 309 D-T interactions from DBv4Rel that were successfully
identified by DReSMin (Figs. 8D and 8E). The average number of semantic
subgraphs that have mappings inferring the 309 annotated D-T associations
captured in DBv4Rel is increased >4 fold in comparison to the number of
semantic subgraphs that produce mappings that infer interactions not captured in
DBv4Rel (Fig. 8F).
DBv4Rel ¼ ðDatRel [ UniqueðDBv4:2ÞÞ \ DBv3Rel j
d 2 DatRelðdÞ ^ t 2 DatRelðtÞ (6)
Looking in more detail at the top 20 inferred D-T interactions (Table 2) we see
12 different drugs and eight targets. Drugs include: three antiarrythmic calcium channel
blockers (Verapamil, Mibefradil and Bepridil); three phenothiazine antipsychotic agents
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Figure 7 Examples of semantic subgraphs drawn from the semantic shortest paths. Q1–Q10 are
drawn from the semantic shortest paths that represented the shortest path between the greatest number
of D-T interactions in DBv3Rel and Q108 is an example of a more complex semantic subgraph. Note:
Dashed red lines represent the inferred binds_to relations, squares represent compounds, circles targets,
diamonds proteins and octagon diseases. For relation types: bi_to = binds_to, sim = similar_to, h_s_s =
has_similar_sequence, ma_tr = may_treat, inv_in = involved_in and is_a = is_a.
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(Promazine, Perphenazine and Thioridazine); three atypical antipyschotic agents
(Propiomazine, Clozapine and Quetiapine); two anticonvulsants (Zonisamide and
Levetiracetam) and one antiarrythmic adrenergic beta-antagonist (Propranolol). Of the
12 drugs captured in the top ranked inferred D-T interactions, the average number of D-T
interactions captured in Dat is ∼13, with the average number for all compounds being
closer to three. The compounds present in the top 20 inferred D-T interactions are well
studied and annotated and are thus highly connected in Dat. Targets include four voltage-
dependant calcium channels (VDCC) and four G-Protein coupled receptors (GPCR).
VDCCs display selective permeability to calcium ions which enter a cell, and alter a
channel’s properties, through the pore which is formed by the a 1 subunit. We can see that
three sub-types of VDCC are represented in Table 2, being: L-type (CAC1C and CAC1D);
P/Q Type (CAC1A) and N-type (CAC1B). Members of the GPCR superfamily in Table 2
include receptors activated by the neurotransmitters: serotonin (5HT7R and 5HT2B);
epinephrine (ADA1A) and dopamine (DRD1).
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Figure 8 Validation of inferred D-T associations with known D-T associations from DBv3 and DBv4.2. (A, B and C) show how DReSMin
identifies and ranks the 2,919 known interactions from DBv3 when searching Dat. (D, E and F) show how DReSMin identifies and ranks the 333
known interactions from DBv4.2. For (A and D) hypergeometric distribution of inferred knowns were calculated using the scores of the validated
associations. For (B and E) hypergeometric distribution of inferred knowns were calculated using the ranked position of the validated interactions.
(C and F) show the number of semantic subgraphs that inferred knowns in comparison to the number of semantic subgraphs that inferred novel
interactions. Note: Blue line shows the highest scoring semantic subgraph; all scores above this line are definitely inferred by > one semantic
subgraph.
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The ability of DReSMin to predict novel D-T interactions was compared to the state-of-
the-art ligand-based method from ChEMBL. We first examined how many D-T
interactions were predicted by both methods (co-prediction) using interactions captured
in the sets DReS, Chem1 and Chem10. 35% of the top x D-T interactions inferred by
DReSMin are found in the top x D-T interactions predicted by ChEMBL models (Figs. 9A
and 9D). More interestingly is the fact that DReSMin successfully infers 10% more of the
knowns from DBv4Rel than ChEMBL, for both models (Figs. 9C and 9F). We found that
DReSMin is able to rank the known D-T interactions more effectively than ChEMBL, with
a mean ranking position of known D-T interactions from DBv4rel of 16,977, as opposed
to the 47,618 achieved by ChEMBL (47,746 for 1 uMmodel and 47,490 for 10 uMmodel).
We must recognise the fact that the semantic subgraphs used during this work were
derived using DrugBank data and the ChEMBL models trained on ChEMBL data.
Target class comparison
After classifying all human proteins in Dat we identify: 826 GPCRs; 343 ion channels;
638 kinases; and 560 proteases. Of the 9,643,061 D-T interactions inferred by DReSMin,
4,780,935 (49.6%) involve human protein targets with 103 GPCRs; 85 ion channels;
Table 2 DReSMin was executed using the 194 semantic subgraphs that represented the shortest path between the drugs and targets captured
in the relevant associations.
Drug (DrugBank ID) Type, Category Inferred Target (Uniprot ID) Evidence # Subs Score
Verapamil (DB00661) SM, AP CAC1C (Q13936) Y 85 0.49211
Mibefradil (DB01388) SM, WI CAC1A (O00555) 74 0.44378
Mibefradil (DB01388) SM, WI CAC1B (Q00975) 59 0.43097
Promazine (DB00420) SM, AP ADA1A (P35348) Y 117 0.39090
Quetiapine (DB01224) SM, AP 5HT7R (P34969) 61 0.38779
Propiomazine (DB00777) SM, AP 5HT7R (P34969) 69 0.38774
Verapamil (DB00661) SM, AP CAC1A (O00555) Y 78 0.38436
Verapamil (DB00661) SM, AP CAC1B (Q00975) Y 64 0.38180
Mibefradil (DB01388) SM, WI CAC1D (Q5SQC4) 52 0.37525
Perphenazine (DB00850) SM, AP 5HT7R (P34969) 86 0.37383
Thioridazine (DB00679) SM, AP 5HT7R (P34969) 75 0.36830
Promazine (DB00420) SM, AP 5HT7R (P34969) 75 0.36824
Propranolol (DB00571) SM, AP, IN DRD1 (P21728) 96 0.36084
Zonisamide (DB00909) SM, AP, IN CAC1B (Q00975) 50 0.35478
Levetiracetam (DB01202) SM, AP, IN CAC1B (Q00975) Y 50 0.35478
Thioridazine (DB00679) SM, AP 5HT2B (P41595) 107 0.35036
Clozapine (DB00363) SM, AP 5HT7R (P34969) Y 64 0.34799
Propranolol (DB00571) SM, AP, IN ADA1A (P35348) 84 0.34663
Bepridil (DB01244) SM, AP, WI CAC1C (Q13936) 77 0.34610
Levetiracetam (DB01202) SM, AP, IN CAC1A (O00555) 63 0.34605
Notes:
See Table S4 for a detailed scoring of the 194 semantic subgraphs. Scores are used as a ranking method for inferred interactions. Of the 20 interactions ranked highest by
DReSMin, six were found in DBv3; having literature supporting their existence. For drug Type and category: SM, small molecule; AP, approved; IN, investigational and;
WI, withdrawn. Scores are to 5 decimal places. # Subs refers to the number of semantic subgraphs that inferred the D-T interaction, with the maximum being 194.
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89 kinases; 60 proteases; and 782 others are captured. In Fig. 10A we see how the target
classes defined are represented in the inferences made by DReSMin. 89% of proteins are
classed as ‘other’, and make up the targets in 69% of all inferences. GPCR’s make up only
4% of all proteins and yet are involved in nearly 10% of all inferences. Only 3.2% of all
proteins are classed as kinases, yet these are captured in 7.9% of all inferences. Proteases
make up 2.8% of proteins and are shown to be part of 5.4% of all inferences. Finally, ion
channels make up 1.7% of proteins and are contained in 7.4% of all predicted D-T
associations.
Ion channels make up the second smallest set of comparative inferences, behind only
proteases, however Fig. 10A shows us that this class is inferred by, on average: the highest
scoring predictions (using Eq. 4); the highest ranked inferences; and the most semantic
subgraphs per inference. Second is the GPCRs, followed by proteases, others and finally
kinases.
Figure 10B shows how highly ranked the D-T interactions captured in DBv3Rel are
ranked in each of the classes. D-Tassociations captured in DBv3Rel are ranked highest for
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Figure 9 DReSMin inferred D-Tassociations in comparison to those inferred using the ligand-based similarity models provided by ChEMBL.
Top graphs (A, B and C) show comparison to those using the 1mM model from ChEMBL and bottom graphs (D, E and F) show comparison with
the 10mM model. (A and D) show the % crossover between the top ranked x associations from each method for each drug. (B and E) show the
comparative ranking of the 2,919 known D-T interactions from DBv3Rel. (C and F) show the comparative ranking of the 333 known D-T
interactions from DBv4Rel. In (B, C, E and F) red diamonds show the mean ranking and numbers in red show the number of knowns captured by
each method. Only associations inferred by the 2,223 drugs with a mapping between DrugBank and ChEMBL and those that contain the over-
lapping set of target proteins are included in comparison.
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GPCRs, followed by: ion channels; proteases; other; and kinases. Known associations from
all classes are, on average, ranked in the top 6% of all inferred associations.
Completing the drug-target-disease pathway
The highest ranked D-T interaction identified by DReSMin, receiving a score of 0.49211,
is supported by the literature and therefore known to the scientific community. This D-T
interaction is between one of the antiarrythmic calcium blockers, Verapamil, and CAC1C.
Within Dat eight indications are associated to Veparamil and 12 diseases associated to
CAC1C. One indication, hypertension, shares a has_Indication association with Verapamil
and a involved_in association with CAC1C. Although Verapamil is already used to treat
hypertension, and the inferred D-T interaction already known, we see how DReSMin may
be used to help understand the molecular mechanism of a drug and thus complete the
‘drug-target-disease’ pathway. Understanding the molecular mechanisms of drugs can
only aid the identification of repositioning opportunities. In Fig. 11 we see examples of
unsupported, and therefore novel, DReSMin inferred D-T interactions that also increase
understanding of the molecular mechanisms involved in a drug’s ability to treat a disease.
Like Verapamil, Bepridil is also a calcium channel blocker with known antiarrhythmia
activities. Used as a treatment of hypertension, we can see in Table 2 an inferred D-T
association involving Bepridil and CAC1C. Bepridil is one of the two drugs from Table 2
that have been withdrawn from the market due to safety concerns. For this reason it is not
0
20
40
60
80
100
Percent_HUMAN
Percent_INF
Percent_nrINFTARGS
Percent_CLASS
[2,2,2] [1,1,1] [5,5,5] [4,4,4] [3,3,3]
%
G
PC
R
Io
n 
Ch
an
ne
l
Ki
na
se
O
th
er
Pr
ot
ea
se
A
0e+00
3e+06
6e+06
9e+06
R
an
ki
ng
 P
os
iti
on
G
PC
R
Io
n 
Ch
an
ne
l
Ki
na
se
O
th
er
Pr
ot
ea
se
B
Figure 10 Target classes.Human proteins in Dat were assigned to one of five target classes: kinases, ion
channels; G protein coupled receptors (GPCR); proteases; or other. (A) shows % of the total set of
human proteins assigned to each class (Percent_HUMAN), what % of all DReSMin inferred associations
contained a protein target from that class (Percent_INF), the % of the unique targets inferred by
DReSMin that were from that class (Percent_nrINFTARGS) and the % of the target class for which an
inference was made (Percent_CLASS). (B) shows how the known associations captured in DBv3Rel were
ranked in the DReSMin inferred D-T interactions, with 1 being the highest ranked association.Note: Sets
of numbers above each class in A represent how the target class ranked in performance in comparison to
the other classes in the following measures: the average score of inferred interactions; the average ranking
of inferences for that class; and the average number of semantic subgraphs that made an individual
inference for that class. 1 represents the best performing target class and 5 the worst.
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a strong candidate to be repositioned, however, via the inferred association we are able to
better understand the molecular mechanism of the drugs ability to treat hypertension
(Fig. 11A).
In Dat we see three indications for Quetiapine (Psychotic Disorders, Bipolar Disorders
and Autistic Disorders) and three involved_in associations involving 5HT7R
(Schizophrenia, Pain and Muscular Diseases). Although a has_Indication association is
not captured in Dat, Quetiapine is approved for the treatment of Schizophrenia. By
integrating this knowledge with Dat and our inferred associations we can complete
another drug-target-disease pathway (Fig. 11C). Schizophrenia, like many disorders, is a
child of psychotic disorders. Although our dataset provides evidence showing Quetiapine
is used to treat the parent term of Schizophrenia, psychotic disorders, the inference made
allows for a better understanding of the drug-target-disease pathway in a more specific
disease area to be achieved.
Propranolol
One inferred D-T interaction in Table 2 involves the antiarrythmic adrenergic
beta-antagonist, Propranolol, and the G protein-coupled receptor DRD1. In Dat we
capture 12 indications for Propranolol and 17 disease associations for DRD1, with one
indication, Hypertension, involved in both an indication association for Propranolol and
a disease association for DRD1 (Fig. 12). Of the remaining 16 involved_in associations
involving DRD1 three of the diseases represent known off-label indications for
Propranolol being: Bipolar disorders; Schizophrenia, Alcoholism and as a non-stimulant
treatment for ADHD (Gobbo & Louza˜, 2014). The remaining 12 diseases present and
support some interesting repositioning opportunities/studies of potential repositioning
opportunities for Propranolol.
Looking at potential indications of Propranolol that are currently being investigated by
the scientific community we see three that are supported by our work. Dat contains an
association between DRD1 and cocaine related disorders, with multiple clinical trials
being undertaken to analyse the use of Propranolol as a treatment for cocaine addiction
(NIDA, 2010) as well as cocaine cravings (Medical University of South Carolina, 2015).
A trial looking at the use of Propranolol as a treatment for Autism is also, at the time of
writing, recruiting (University of Missouri-Columbia, 2015). Finally, a clinical trial has also
A
Hypertension
Bepridil
B
CAC1C Perphenazine
Schizophrenia
5HTR7
C
Quetiapine
Schizophrenia
5HTR7
Figure 11 Drug-target-disease pathways completed via inferred D-T associations. Data presented is
extracted from Dat with one association extracted from literature. Note: Dashed lines represent the
inferred binds_to relations, zig-zag lines represent has_Indication relation not captured in Dat and
extracted from literature, squares represent compound, circles target and octagon diseases.
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been undertaken to analyse the effects of using Propranolol as a treatment for
drug-induced movement disorders (Merck Sharp & Dohme Corp., 2014). We can see
that our inferred D-T interactions allow us to predict repositioning opportunities that
agree with the community.
DISCUSSION
In this paper, we explore the concept of using semantic subgraphs as a way of inferring
novel D-T interactions with the aim of using them to identify drug repositioning leads.
We present and formalise semantic subgraphs, showing how they may present patterns
indicative of drug repositioning opportunities. By employing a novel approach to
reducing the target graph size prior to a search, and by breaking larger semantic subgraphs
to a set of smaller subgraphs, DReSMin significantly improves on the performance of a
purely topological approach to pattern matching. We also show how the approach can be
used to automate the identification of novel D-T interactions in an integrated semantic
network, with the aid of historical data. This real-world problem often requires searching
for semantic subgraphs where jV(Q)j > 4. The optimisations we have presented here
makes searching for instances of these complicated subgraphs computationally tractable
and scalable. We have shown an example of the application of DReSMin which highlights
the potential of the approach.
Pheochromocytoma 
Tachycardia Ventricular
Essential Tremor
Hypertension Portal
Heart Failure
Myocardial Infarction 
Anxiety Disorders
Bipolar Disorder
Hallucinations
Alcoholism
Autistic Disorder
Hypotension
Catelepsy
Movement Disorders
Alzheimer Disease
Attention Deficit Disorder with 
Hyperactivity 
Dyskenisia Drug Induced
Cocaine Related Disorders
DRD1
Huntington Disease
Schizophrenia
Substance Related Disorders
Pyschotic Disorders
Amphetamine Related Disorders
Hypertension
Tachycardia supraventricular
Panic Disorder
Propranolol
Angina Pectoris
Esophageal and Gastric Varices
Figure 12 Diseases associated with Propranolol and DRD1. Drug-disease has_Indication associations
involving Propranolol and gene-disease involved_in associations were extracted from Dat. Note: Dashed
lines represent the inferred binds_to relations, squares represent compound, circles target and octagon
diseases.
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When comparing DReSMin to other state-of-the-art drug-target prediction methods
we observe an average co-prediction of 35%. Although this still leaves a large proportion
of unique inferences we show that DReSMin inferences identify >16% of the knowns
when using DBv3, and >10% of the knowns when using DBv4, in comparison to
ChEMBL. The ability of DReSMin to identify more of the knowns than ChEMBL supports
the approach and provides evidence that the approach provides an improved prediction
set. We then directly compared and contrasted the results and found DReSMin to
outperform the ChEMBL models at inferring annotated DrugBank D-T interactions.
Considering DReSMin is a general algorithm, not specifically developed for the inference
of D-T interactions, this highlights its potential ability to compete with specialised
approaches. Although the semantic subgraphs used to search Dat were derived from the
shortest paths between a drug and target from D-T interactions in DBv3, these
interactions were inferred, on average, by around 40 different semantic subgraphs. This is
in contrast to the 15 semantic subgraphs that inferred D-T interactions not captured in
DBv3. Again this validates the approach we employed during this work. Annotated D-T
interactions were not only captured by the semantic subgraph derived from the semantic
shortest path between their drug and target but also by many more.
We show that DReSMin is able to identify known D-T interactions regardless of the
class to which the target belongs. Having said this, the approach works better for target
classes where there exists a relatively high amount of information, such as GPCRs and ion
channels, whose knowns fall, on average, in the top 2% of inferred D-T interactions.
Knowns involving other classes, such as kinases, for which there is less information, are
still, on average, captured in the top 6% of all DReSMin inferred D-T associations. Our
approach makes use of the holistic view of an entity and so if less is known about a target it
will be captured in fewer semantic subgraphs and thus D-T interactions that it is predicted
to be involved in will obtain a lower score. The data bias will become less of a problem
as more and more data is produced for target classes such as proteases and kinases.
Although DReSMin at present scores semantics based purely on the most abstract form
of types, it could be beneficial to include scoring metrics based on node and edge
attributes, and the data-sources from which they are retrieved. For example, during the
process of data integration it would be useful to consider dataset quality during the
construction of the integrated graph and apply annotations that indicate a measure of
confidence in a given interaction. To this end we are currently developing a new integrated
dataset that will allow provenance and data to reliability to be scored during a search. This
modification will allow the scoring of semantic subgraphs to be not only topological and
semantic but also based on the reliability of the source of each element.
DReSMin is very capable of prioritising known D-T interactions, however, in order for
inferences made to be useful to drug repositioning there are still some limitations that
must be discussed. We illustrate these limitations with some examples. First of all,
DReSMin infers an interaction between Dexrazoxane (DB00380) and Dactinomycin
(DB00970) and the Sodium channel protein type 1 subunit alpha (P35498). This target is
located predominantly in the brain and is heavily associated with epilepsy (Mantegazza
et al., 2010; Escayg & Goldin, 2010). To reach the brain a drug must cross the blood-brain
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barrier (BBB). Restricted by their pharmacokinetics, multiple drugs, such as Dexrazoxane
(DB00380) and Dactinomycin (DB00970) (Holm et al., 1998), are unable to cross the BBB
and so this inference is unlikely to highlight any realistic repositioning opportunity.
Secondly, DReSMin infers D-T interactions involving drugs from a range of marketed
states. Examples include drugs that have been withdrawn due to the fact that they are not
as effective as first thought, such as Drotrecogin alfa (DB00055) in the treatment of sepsis,
or due to poor sales, such as Halazepam (DB00801); interesting candidates for
repositioning. Drugs that have been withdrawn from the market for reasons involving
safety concerns prove a more problematic repositioning opportunity. Some examples are
included in DReSMin inferences, such as drugs that have been withdrawn from market
due to potentially fatal side effects, such as: Metamizole (DB04817); Grepafloxacin
(DB00365); and Temafloxacin (DB01405). Finally, DReSMin inferred an association
between Domperidone (DB01184) and the Beta-1 adrenergic receptor (P08588). Heart
palpitations are a known side-effect of Domperidone and Beta-1 adrenergic antagonists,
such as Propranolol have been administered to those suffering heart palpitations. One can
thus deduce that Domperidone may have some agonistic action upon the Beta-1
adrenergic receptor. With these examples in mind other properties must be considered in
further extensions to the approach. Drug properties, such as pharmacokinetics, in relation
to the target location must be considered as well as a pre-filtering step to remove all drugs
from the search that are likely unsafe. Post-filtering of results based on the likelihood of an
D-T interaction prediction leading to a potential side-effect would also be a useful
addition.
In the approach described here semantic subgraphs are derived from only the node
types and edge types that fall directly on the semantic shortest path between a drug and a
target. In order for a semantic subgraph capture even more functional detail it may be
beneficial to expand the view that the subgraph takes of its immediate neighbourhood. To
this regard we are currently considering extending semantic subgraphs to include nodes
that interact with those in the semantic shortest path at a particular depth.
Although we present an exhaustive automated approach it is also worth noting that
semantic subgraphs can be drawn from real life repositioning examples via manual
curation. The manual development of semantic subgraphs, such as the one described in
Fig. 1, is time consuming. However, manually curated semantic subgraphs may allow for
more accurate representations of a functional module capturing a potential drug
repositioning opportunity, as opposed to those created via automated approaches. We
hope to create a library of semantic subgraphs curated from real world examples of
repositioned drugs and compare the accuracy and efficiency to the semantic subgraphs
developed during this work.
With regard to the mining algorithm, as new graph mining frameworks emerge with
efficient graph searching algorithms (e.g. Neo4J), it may be possible to exploit
these built in algorithms to implement sections of the approach we describe here.
However, necessarily, the nature of these implementations will depend on the
specific graph database.
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We have demonstrated that our algorithm may be used to infer D-T interactions,
however, like all in silico approaches to analysing in vivo and in vitro systems the accuracy
is limited; overly simplified settings innately struggle to reflect real-life problems. Our
approach, unlike many other computational approaches to drug repositioning, is not
limited to the inference of D-T interactions. Semantic subgraphs may be designed to infer
relations between any conceptClasses in a dataset and can be used to infer a drugs
indication, mode of action, side effect and more. We believe that the systems biology
approach that we describe here will allow for a more accurate, holistic, systematic
approach to drug repositioning.
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